Tevogen Bio (TVGN) said Monday it filed a new patent with the US Patent and Trademark Office for its T cell vaccine that is currently under development.
The company said the vaccine's design aims to use its Tevogen.AI-powered PredicTcell technology to identify peptides that stimulate a T cell response, unlike vaccines that mainly induce a B cell response.
Tevogen Bio said that similar to its lead product candidate TVGN 489, the vaccine can target the entire viral genome, helping to mitigate a risk posed by mutations.
The company's shares were down over 5% in recent trading.
Price: 1.08, Change: -0.06, Percent Change: -5.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。